Metastatic Breast Cancer
Feature
Immunotherapy May Be Overused in Dying Patients With Cancer
“There are patients who are getting immunotherapy who shouldn’t,” according to a surgical oncologist from Yale.
From the Journals
Modest Gains Shown in Breast Cancer Immunotherapy Trials
Researchers evaluated 331 immunotherapy trials, enrolling nearly 50,000 patients with breast cancer.
From the Journals
Can Addressing Depression Reduce Chemo Toxicity in Older Adults?
Researchers evaluated whether greater reductions in grade 3 chemotherapy-related toxicities occurred with geriatric assessment-driven...
News from the FDA/CDC
FDA Approves First Engineered Cell Therapy for a Solid Tumor
This T-cell receptor therapy modifies existing receptors to recognize an array of antigens on the surface of cancer cells.
From the Journals
Ancient Viruses in Our DNA Hold Clues to Cancer Treatment
Targeting remnants of a virus in our DNA could lead to more effective cancer treatment with fewer side effects.
Feature
Greater Transparency of Oncologists’ Pharma Relationships Needed
Reducing industry payments to hematologists and oncologists could benefit patients, say experts.
Conference Coverage
Cognitive Decline Minimal After Endocrine + CDK4/6 Inhibition in BC
Authors investigate cognitive functioning in the same cohort used in the SONIA trial and a matched control group of individuals that did not have...
Conference Coverage
Eribulin Similar to Taxane When Paired With Dual HER2 Blockade in BC
Patients with HER2-positive, locally advanced or metastatic breast cancer who cannot tolerate the standard taxane-based regimen have a new option...
Conference Coverage
PFS Benefits Seen With Palbociclib + Endocrine Therapy in Breast Cancer
Palbociclib plus endocrine therapy or chemotherapy: Which is best in HR+/HER2- metastatic breast cancer?
From the Journals
Should Cancer Trial Eligibility Become More Inclusive?
A new study highlights the potential benefits of broadening eligibility criteria for clinical trials.
Feature
New ADC results mixed in metastatic breast cancer
While T-DXd showed promise for yet another indication at ASCO, other findings underscored that much still remains to be learned about this drug...